Evercyte bringing range of new offers to ToxExpo 2018
Press Release | Evercyte GmbH
MARCH 07, 2018
Vienna, Austria: – Innovative biotech manufacturer Evercyte is heading back to the highly respected Society of Toxicology meeting, ToxExpo, for the third year in succession.
Evercyte will use the meeting, this year being held in San Antonio, Texas, to present a range of services based on its expertise in customer-tailored cell line development of human cell lines and gene editing studies.
Products and services offered:
- Human podocyte cell line immortalized by telomerase: important kidney toxicology model that complements Evercyte’s respected proximal tubular cell line RPTEC/TERT1 for any kidney toxicity study in vitro
- Human bronchial epithelial cells (HBEC3-KT) immortalized by telomerase: well differentiating cells as model system to study lung disease / cancer and toxicology
- Human corneal epithelial cells (hTCEpi) immortalized by telomerase: allowing the establishment of a standardized, reproducible cornea barrier model for toxicology studies and insights in inflammation and wound healing processes
- hTERT and SV40 early region immortalized human skin keratinocytes (NHEK/SVTERT3-5), providing an important skin model for toxicology studies due to the ability to differentiate towards functional 3D skin equivalents
- Customer tailored human telomerized cells: one-stop solution from tissue sourcing to relevant in-vitro cell models
- Induced pluripotent stem cells (iPSCs): a service that can generate iSPCs from human urine in a fully non-invasive way
“Having previously attended ToxExpo in 2016 and 2017, we will use this 57th meeting to once again present a range of products and services that customers can use to engineer bespoke solutions”, said Evercyte founder and CSO, Johannes Grillari. The acknowledged expert in cell and molecular biology will be leading the company’s presence in San Antonio.
“Once again, we will reach out to academics and scientists in pharmaceutical, chemical and cosmetic industries, as well as researchers in academia, hoping to meet them face to face,” said Dr. Grillari.
“For scientists in CROs offering in vitro cell based assays, we can open up exciting opportunities to use human telomerized cells as the most robust and reproducible system for cell-based assays and in vitro toxicology due to unlimited cell supply,” added Dr. Grillari.
Targeted CrispR/Cas9 gene insertion
“The key point is that primary key functionalities and genetic stability upon life span extension of the cells are maintained and not changed. These cells are the only surrogate of primary cells that can be gene edited for functional studies, fast reporter gene assays using targeted insertion of genes by CrispR/Cas9,” he explained.
“Thus, orthogonal screenings in phenotypic drug screening or target screenings are possible in isogenic human cell lines. Functional studies for adverse outcome pathways (AOP) in vitro are possible,” Dr. Grillari concluded.
Evercyte GmbH, based in Vienna, manufactures a range of innovative cell-based products; including primary/normal cells; telomerase (hTERT) immortalized or life span extended cells and differentiated cells from immortalized or normal stem cells.
Recently, Evercyte has become a key player in the development of induced pluripotent stem (iPS) cells from human urine as a non-invasive source for generating cell material. The company also offers a range of cell-based assays, used in development of drug screening strategies and other applications. It also develops assays to individual specification to help customers reduce their time and spend on drug discovery and development.
Evercyte’s Pharmacocellomics™ is also improving the predictability of substance efficiencies and side effects in the general population by systematically establishing and commercializing relevant cell type specific model systems from donors of different genetic backgrounds.
About ToxExpo 2018
ToxExpo™ is the annual meeting of the US Society of Toxicology that brings together toxicologists from around the world to share research and expertise and find new collaborators.
The 57th Annual Meeting, ToxExpo 2018, is a five-day event, opening March 12 at the Baltimore Convention Center in Maryland. It is expected to attract some 6,800 attendees and more than 350 toxicology-related companies and organizations from some 50 countries.
The 2018 meeting will feature more than 160 scientific sessions, featuring nearly 2,500 abstracts, as well as a co-hosted exhibition.
The event is organized by the Society of Toxicology, based in Reston, VA. More information at: http://www.toxicology.org/events/am/AM2017.
Irene Redlinghofer, Business Development and Project Management, Evercyte GmbH
Tel: +43 699 107 09 401